Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial

[1]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  P. Liu,et al.  Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy , 2018, Medicine.

[3]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[4]  E. Warner,et al.  Ovarian function after chemotherapy in young breast cancer survivors. , 2017, Current oncology.

[5]  C. Criscitiello,et al.  Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jia Wei,et al.  Feasible and efficient identification of neoantigens for personalized cancer immunotherapy in advanced refractory epithelial cancer patients. , 2017 .

[7]  M. Hsieh,et al.  Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. , 2017, Urology.

[8]  M. Somerfield,et al.  Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Starosławska,et al.  Life quality of women with breast cancer after mastectomy or breast conserving therapy treated with adjuvant chemotherapy. , 2015, Annals of agricultural and environmental medicine : AAEM.

[10]  Thomas J. Smith,et al.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Lori A. Eggert,et al.  Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients , 2015, Supportive Care in Cancer.

[12]  D. Warr.  Management of highly emetogenic chemotherapy , 2012, Current opinion in oncology.

[13]  G. Nocea,et al.  Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life , 2012, Supportive Care in Cancer.

[14]  Marcus Schmidt,et al.  Adjuvant chemotherapy in early breast cancer. , 2012, Minerva Ginecologica.

[15]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Goodwin,et al.  Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). , 2011, Journal of the National Cancer Institute.

[17]  E. Perez,et al.  Changes to adjuvant systemic therapy in breast cancer: a decade in review. , 2010, Clinical breast cancer.

[18]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  S. Grunberg.  Obstacles to the implementation of antiemetic guidelines. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  Edith A Perez,et al.  Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Sledge,et al.  Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study , 2008, Breast Cancer Research and Treatment.

[22]  R. Gray,et al.  Randomized clinical trial design for assessing noninferiority when superiority is expected. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Ward,et al.  Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. , 2007, Health technology assessment.

[24]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[25]  G. Guyatt,et al.  The clinical significance of quality of life assessments in oncology: a summary for clinicians , 2006, Supportive Care in Cancer.

[26]  M. Milella,et al.  Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.

[27]  M. Stockler,et al.  Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.

[28]  P. Ganz,et al.  Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock. , 2003, Journal of the National Cancer Institute.

[29]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Riva,et al.  Taxane/anthracycline combinations: setting a new standard in breast cancer? , 2001, The oncologist.

[31]  A. Wolff,et al.  Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[33]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Koelemay,et al.  Health and Quality of Life Outcomes , 2009 .

[35]  Ali Montazeri,et al.  Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007 , 2008, Journal of experimental & clinical cancer research : CR.

[36]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Sparano,et al.  Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.